Inspire Medical Systems (NYSE:INSP) Updates FY 2026 Earnings Guidance

Inspire Medical Systems (NYSE:INSP – Get Free Report) issued an update on its FY 2026 earnings guidance on Monday. The company provided EPS guidance of 1.050-1.450 for the period, compared to the consensus EPS estimate of 0.910. The company issued revenue guidance of $835.0 million-$875.0 million, compared to the consensus revenue estimate of $848.9 million.

Wall Street Analyst Weigh In

A number of research analysts have recently weighed in on INSP shares. Mizuho cut their price target on shares of Inspire Medical Systems from $70.00 to $55.00 and set an “outperform” rating on the stock in a report on Tuesday, May 5th. Stifel Nicolaus lowered their target price on shares of Inspire Medical Systems from $70.00 to $65.00 and set a “buy” rating on the stock in a research report on Tuesday, May 5th. Summit Redstone set a $39.00 target price on shares of Inspire Medical Systems in a research report on Friday, May 22nd. Evercore lowered Inspire Medical Systems from an “outperform” rating to an “in-line” rating and set a $40.00 target price on the stock. in a report on Tuesday, June 23rd. Finally, Zacks Research raised Inspire Medical Systems from a “strong sell” rating to a “hold” rating in a research report on Monday, July 6th. One equities research analyst has rated the stock with a Strong Buy rating, four have assigned a Buy rating, thirteen have issued a Hold rating and three have assigned a Sell rating to the company’s stock. Based on data from MarketBeat, the stock currently has an average rating of “Hold” and a consensus target price of $73.28.

Get Inspire Medical Systems alerts:

Read Our Latest Report on INSP

Inspire Medical Systems Stock Performance

Shares of Inspire Medical Systems stock traded up $2.01 on Monday, reaching $52.22. The stock had a trading volume of 964,586 shares, compared to its average volume of 1,163,503. The business’s 50-day moving average price is $45.98 and its two-hundred day moving average price is $55.45. The stock has a market cap of $1.50 billion, a P/E ratio of 11.63, a price-to-earnings-growth ratio of 5.08 and a beta of 0.71. Inspire Medical Systems has a fifty-two week low of $38.91 and a fifty-two week high of $147.03.

Inspire Medical Systems (NYSE:INSP – Get Free Report) last posted its earnings results on Monday, August 3rd. The company reported $0.14 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.24) by $0.38. The business had revenue of $200.58 million for the quarter, compared to analyst estimates of $194.72 million. Inspire Medical Systems had a net margin of 14.33% and a return on equity of 10.35%. Inspire Medical Systems has set its FY 2026 guidance at 1.050-1.450 EPS. As a group, equities analysts forecast that Inspire Medical Systems will post 0.93 earnings per share for the current fiscal year.

Hedge Funds Weigh In On Inspire Medical Systems

Several large investors have recently made changes to their positions in INSP. Royal Bank of Canada grew its holdings in Inspire Medical Systems by 16.0% in the 1st quarter. Royal Bank of Canada now owns 32,769 shares of the company’s stock valued at $5,220,000 after buying an additional 4,528 shares during the last quarter. Integrated Wealth Concepts LLC acquired a new position in shares of Inspire Medical Systems during the first quarter worth approximately $524,000. Goldman Sachs Group Inc. boosted its position in shares of Inspire Medical Systems by 57.9% in the first quarter. Goldman Sachs Group Inc. now owns 51,422 shares of the company’s stock valued at $8,190,000 after acquiring an additional 18,857 shares during the period. Marshall Wace LLP boosted its position in shares of Inspire Medical Systems by 3.8% in the second quarter. Marshall Wace LLP now owns 15,905 shares of the company’s stock valued at $2,064,000 after acquiring an additional 577 shares during the period. Finally, Jump Financial LLC acquired a new stake in shares of Inspire Medical Systems in the second quarter worth $931,000. Institutional investors and hedge funds own 94.91% of the company’s stock.

About Inspire Medical Systems

(Get Free Report)

Inspire Medical Systems, Inc is a medical technology company specializing in implantable neurostimulation devices for the treatment of obstructive sleep apnea (OSA). The company’s flagship offering, the Inspire® system, delivers targeted stimulation of the hypoglossal nerve to maintain airway patency during sleep, providing an alternative therapy for patients who are intolerant of or inadequately managed by continuous positive airway pressure (CPAP) devices.

The Inspire system comprises an implantable pulse generator, a sensing lead that monitors breathing patterns, and a stimulation lead that activates the hypoglossal nerve.

Featured Stories

• Five stocks we like better than Inspire Medical Systems
• SpaceX’s First Earnings Report Could Decide Whether Shorts or Bulls Have Control
• Why Rare Earth Processing Could Be the Real 2027 Opportunity
• The S&P 493 Are Staging a Comeback—This Value ETF Offers Broad Exposure
• TSMC Insiders Are Buying the Pullback—But Is the Signal as Bullish as It Looks?

Receive News & Ratings for Inspire Medical Systems Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Inspire Medical Systems and related companies with MarketBeat.com's FREE daily email newsletter.